Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Other ASCO 2018 Highlights – It’s Not All IO

18 May 2018

• By Emily Hayes and Jessica Merrill

Digital illustration of Cancer cell in colour background

Related Content

Agios' IDH Inhibitors Show Their Mettle At ASH

12 Dec 2017

Rolontis Leads Hanmi’s Global Ambitions As ADVANCE Phase III Endpoint Met

09 Feb 2018

More Deals Like Loxo On The Cards As Bayer Ups Ante In Oncology

06 Mar 2018

Immuno-Oncology: What To Watch At ASCO 2018

18 May 2018

HR+/HER2- Breast Cancer Market Set To Triple

05 May 2016

Pfizer drug fails in two Phase III lung cancer studies

28 Jan 2014

Loxo's Larotrectinib Requires Paradigm-Change In Clinical Practice

05 Jun 2017

Related Companies

Pfizer Inc.

AstraZeneca PLC

G1 Therapeutics Inc.

Roche Holding AG

Loxo Oncology at Lilly

Bayer AG

Blueprint Medicines Corporation

Novartis AG

Eli Lilly and Company

Spectrum Pharmaceuticals, Inc.

Hanmi Pharmaceutical Co., Ltd.

Agios Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Additional Topics

Clinical Trials Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.